ALL [clinicaltrials_resource:5fb1f955b45e38e31789286a1790398d]
clinicaltrials:NCT00013533clinicaltrials:NCT00252057CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation [clinicaltrials:NCT00333190]Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders [clinicaltrials:NCT00511537]Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders [clinicaltrials:NCT00533923]clinicaltrials:NCT00539695Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders [clinicaltrials:NCT00636909]Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies [clinicaltrials:NCT00776373]clinicaltrials:NCT00814983Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) [clinicaltrials:NCT00815568]Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) [clinicaltrials:NCT00863148]Umbilical Cord Blood Transplant for Hematological Malignancies [clinicaltrials:NCT00891592]A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00964873]clinicaltrials:NCT01012492clinicaltrials:NCT01204164clinicaltrials:NCT01230788clinicaltrials:NCT01319864clinicaltrials:NCT01532635clinicaltrials:NCT01593696A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection [clinicaltrials:NCT01829971]Prediction of Delayed Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With ALL [clinicaltrials:NCT02133599]Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease [clinicaltrials:NCT02158052]Massage Therapy Versus Music Therapy Pilot Study [clinicaltrials:NCT02227680]clinicaltrials:NCT02315612
condition [clinicaltrials_vocabulary:condition]
eligibility for clinicaltrials:NCT00544466 [clinicaltrials_resource:17eda8d4fb5b423a4ae0eb016206e589]eligibility for clinicaltrials:NCT00202917 [clinicaltrials_resource:540656d8a1a623283bf3a0504337ec79]eligibility for clinicaltrials:NCT00972101 [clinicaltrials_resource:b424afb4b8a211a13f358ec140e1f8bb]eligibility for clinicaltrials:NCT00389428 [clinicaltrials_resource:c4a463a9308c0cded03ccf3a0c5e8729]eligibility for clinicaltrials:NCT01050439 [clinicaltrials_resource:d1409751eaf4777f5b5b8d6857d35575]eligibility for clinicaltrials:NCT01919866 [clinicaltrials_resource:dc83511f18eac7b0d104af75891d3286]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00544466 [clinicaltrials_resource:17eda8d4fb5b423a4ae0eb016206e589]eligibility for clinicaltrials:NCT00202917 [clinicaltrials_resource:540656d8a1a623283bf3a0504337ec79]eligibility for clinicaltrials:NCT00824135 [clinicaltrials_resource:57c6b843427e53226aa6a93ca7f9c6e8]eligibility for clinicaltrials:NCT00972101 [clinicaltrials_resource:b424afb4b8a211a13f358ec140e1f8bb]eligibility for clinicaltrials:NCT00389428 [clinicaltrials_resource:c4a463a9308c0cded03ccf3a0c5e8729]eligibility for clinicaltrials:NCT01050439 [clinicaltrials_resource:d1409751eaf4777f5b5b8d6857d35575]eligibility for clinicaltrials:NCT01919866 [clinicaltrials_resource:dc83511f18eac7b0d104af75891d3286]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
ALL [clinicaltrials_resource:5fb1f955b45e38e31789286a1790398d]
Bio2RDF identifier
5fb1f955b45e38e31789286a1790398d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:5fb1f955b45e38e31789286a1790398d
identifier
clinicaltrials_resource:5fb1f955b45e38e31789286a1790398d
title
ALL
@en
type
label
ALL [clinicaltrials_resource:5fb1f955b45e38e31789286a1790398d]
@en